Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Senzer

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancerJohn Nemunaitis, Thomas Meyers, Neil Senzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancerJohn Nemunaitis, Robert O Dillman, Paul O Schwarzenberger, et al.
Communications Medicine|September 2, 2022
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancerRodney P Rocconi, Laura Stanbery, Min Tang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patientsAlex W Tong, John Nemunaitis, Dan Su, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremitiesArno J Mundt, Srinivasan Vijayakumar, John Nemunaitis, et al.
Gastrointestinal Endoscopy|January 18, 2012
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II studyJ Randolph Hecht, James J Farrell, Neil Senzer, et al.
Plos One|August 21, 2012
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platformShi-He Liu, Donald D Rao, John Nemunaitis, et al.
Human Gene Therapy|April 27, 2011
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplexGregory Nemunaitis, Chris M Jay, Phillip B Maples, et al.
Journal of Pediatric Hematology/Oncology|March 25, 2017
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil ImmunotherapyMaurizio Ghisoli, McCarley Rutledge, Philip J Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancerMinal Barve, James Bender, Neil Senzer, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancerJohn Nemunaitis, Thomas Meyers, Neil Senzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancerJohn Nemunaitis, Robert O Dillman, Paul O Schwarzenberger, et al.
Communications Medicine|September 2, 2022
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancerRodney P Rocconi, Laura Stanbery, Min Tang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 9, 2004
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patientsAlex W Tong, John Nemunaitis, Dan Su, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremitiesArno J Mundt, Srinivasan Vijayakumar, John Nemunaitis, et al.
Gastrointestinal Endoscopy|January 18, 2012
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II studyJ Randolph Hecht, James J Farrell, Neil Senzer, et al.
Plos One|August 21, 2012
PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platformShi-He Liu, Donald D Rao, John Nemunaitis, et al.
Human Gene Therapy|April 27, 2011
Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplexGregory Nemunaitis, Chris M Jay, Phillip B Maples, et al.
Journal of Pediatric Hematology/Oncology|March 25, 2017
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil ImmunotherapyMaurizio Ghisoli, McCarley Rutledge, Philip J Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2008
Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancerMinal Barve, James Bender, Neil Senzer, et al.
Pageof 8